82244-11-9

Usage

Uses

Used in Pharmaceutical Synthesis:
Benzyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate is used as an intermediate in the production of drugs that target the central nervous system. Its unique structure allows it to be a key component in the development of medications aimed at treating various neurological disorders.
Used in Research and Development:
In the field of pharmaceutical research and development, Benzyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate is utilized for its potential neurological effects and as a GABA receptor antagonist. This makes it a valuable tool in exploring new avenues for the treatment of neurological conditions and in the discovery of novel therapeutic agents.
Used in the Development of GABA Receptor Antagonists:
Given its activity as a GABA receptor antagonist, Benzyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate is used in the development of drugs that modulate the activity of the GABA receptors, which are crucial in the regulation of neuronal excitability and have implications in the treatment of anxiety, epilepsy, and other related disorders.
Used in the Chemical Industry:
While the primary applications of Benzyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate are in the pharmaceutical sector, its unique chemical properties may also find use in other areas of the chemical industry, such as in the synthesis of other complex organic compounds or as a reagent in various chemical processes.

Upstream product

• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 501-53-1 benzyl chloroformate 
• 311-46-6 ethyl 2-(dimethoxyphosphoryl)acetate 
• 5927-18-4 trimethyl phosphonoacetate 
• 41979-39-9 4-piperidone hydrochloride 
• 95798-23-5 1-(benzyloxycarbonyl)-4-hydroxypiperidine 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 

Downstream Products

• 59184-90-6 ethyl (piperidin-4-yl)acetate 
• 315203-51-1 ethyl 2-(piperidin-4-ylidene)acetate 
• 130312-10-6 benzyl 4-(2-oxoethyl)piperidine-1-carboxylate 
• 115909-91-6 1-(Benzyloxycarbonyl)-4-(2-hydroxyethyl)piperidine 
• 147610-84-2 6-benzyl 1-ethyl 6-azaspiro[2.5]octane-1,6-dicarboxylate 
• 82244-13-1 ethyl 1-carbobenzoxy-3,4-epoxypiperidine-4-acetate 
• 82244-14-2 1-carbobenzoxy-3,4-dihydroxypiperidine-4-acetic acid lactone 
• 82244-15-3 1-carbobenzoxy-Δ^4,α-piperidine-4,3-acetolactone 
• 82244-16-4 cis-1-carbobenzoxypiperidine-4,3-acetolactone 
• 82244-12-0 ethyl 1-carbobenzoxy-1,2,5,6-tetrahydropyridine-4-acetate 

Relevant academic research and scientific papers

PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Piperidine compounds of the Formular: (I) and pharmaceutically acceptable salts thereof, wherein X, Y, R 1, R 2, R 3, L, R 4, L 1, Q and R 5 are as defined herein. The compounds and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Provided herein are certain substituted N-aryl and N-heteroaryl piperidine compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L, R4, L1, Q, R5 and R 6 are as defined. The said novel compounds, and pharmaceutically acceptable compositions comprising a compound thereof, may be useful as Liver X-β receptor(LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory disease and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Substituted aryl and heteroaryl ether compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein X, R 1, R 2, R 3, L, R 4, L 1, Q, and R 5 are as defined herein. These compounds and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES

The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity particularly involved in the development and maintenance of persistent or chronic pain, and / or neurological disorders. These novel compounds are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which these ion channels are involved. The invention is also directed towards pharmaceutical formulations comprising these compounds and the uses of these compounds.

SPIROCYCLOPROPYL PIPERIDINE DERIVATIVES

Disclosed herein is at least one piperidine derivative, at least one pharmaceutical composition comprising at least one piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith

Pd/C(en)-catalyzed chemoselective hydrogenation with retention of the N-Cbz protective group and its scope and limitations

A chemoselective method for the hydrogenation of acetylene, olefin, azide, nitro and benzyl ester functionalities with retention of the aliphatic N-Cbz group was established. The chemoselectivity was accomplished by using a combination of 5% Pd/C-ethylenediamine [5% Pd/C(en)] and THF (or 1,4-dioxane) as a solvent, and the scope and limitations of this methodology were investigated. These results reinforce the utility of N-Cbz protective groups in synthetic chemistry, especially in peptide synthesis. (C) 2000 Elsevier Science Ltd.